Active Ingredients: Norfloxacin
Particles having diameters smaller than about 0. In one embodiment, a nebulizer is selected on the basis of allowing the formation of an aerosol of the pharmaceutical combination disclosed herein having an MMAD predominantly between about 0.
In one embodiment, the delivered amount of the pharmaceutical combination provides a therapeutic effect for respiratory infections.
The nebulizer can deliver an aerosol comprising a mass median aerodynamic diameter from about 0. In some embodiments, the MMAD can be about 0.
In one embodiment, the MMAD ranges from about 2. In another embodiment, the MMAD ranges from about 3. In some embodiments, the nebulizer can be a breath actuated nebulizer BAN.
In some embodiments, the aerosol can be produced using a vibrating mesh nebulizer.
In one embodiment, the nebulizer is a breath actuated nebulizer. The formulation can have a pH from about 1.
In some embodiments, the formulation can have a pH of about 1. In some embodiments, the formulation can have a tonicity of about 50, about 100 mOsm, about 150 mOsm, about 200 mOsm, about 250 mOsm, about 300 mOsm, about 350 mOsm, about 400 mOsm, about 450 mOsm, about 500 mOsm, about 550 mOsm, about 600 mOsm, about 650 mOsm, about 700 mOsm, about 750 mOsm, about 800 mOsm, about 850 mOsm, about 900 mOsm, about 950 mOsm or about 1,000 mOsm.
The formulation can comprise a conventional pharmaceutical carrier, excipient or the like that are approved for inclusion in inhaled products per the US National Formulary and database of approved excipients maintained by USFDA and other regulatory agencies.
Non-limiting examples of carriers and excipients include. Solutions to be aerosolized can be prepared in conventional forms, either as liquid solutions or suspensions, as emulsions, or in solid forms suitable for dissolution or suspension in liquid prior to aerosol production and inhalation.Adults: oral CellCept should be initiated within 72 hours following transplantation area of at least 1.
The percentage of active compound contained in such aerosol compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject.
However, percentages of active ingredient s of about 0. In some embodiments, the composition will comprise 1.
In some embodiments, the composition will comprise about 1. The pharmaceutical combination can be delivered by inhalation by dry powder inhalers, such as Aerolizer, Diskus, Flexhaler, Handihaler, Neohaler, Pressair, Rotahaler, Tubuhaler and Twisthaler; metered-dose inhalers; and nebulizers, such as a breath-actuated wet nebulizer, soft mist inhaler, human powered nebulizer, vibrating mesh nebulizer, jet nebulizer and ultrasonic wave nebulizer.